Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors.

Morgan SB, Holzer B, Hemmink JD, Salguero FJ, Schwartz JC, Agatic G, Cameroni E, Guarino B, Porter E, Rijal P, Townsend A, Charleston B, Corti D, Tchilian E.

Front Immunol. 2018 Apr 24;9:865. doi: 10.3389/fimmu.2018.00865. eCollection 2018.

2.

High-avidity IgA protects the intestine by enchaining growing bacteria.

Moor K, Diard M, Sellin ME, Felmy B, Wotzka SY, Toska A, Bakkeren E, Arnoldini M, Bansept F, Co AD, Völler T, Minola A, Fernandez-Rodriguez B, Agatic G, Barbieri S, Piccoli L, Casiraghi C, Corti D, Lanzavecchia A, Regoes RR, Loverdo C, Stocker R, Brumley DR, Hardt WD, Slack E.

Nature. 2017 Apr 27;544(7651):498-502. doi: 10.1038/nature22058. Epub 2017 Apr 12.

PMID:
28405025
3.

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.

Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ.

Cell. 2016 Jul 28;166(3):596-608. doi: 10.1016/j.cell.2016.05.073. Epub 2016 Jul 21.

4.

Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis.

De Benedictis P, Minola A, Rota Nodari E, Aiello R, Zecchin B, Salomoni A, Foglierini M, Agatic G, Vanzetta F, Lavenir R, Lepelletier A, Bentley E, Weiss R, Cattoli G, Capua I, Sallusto F, Wright E, Lanzavecchia A, Bourhy H, Corti D.

EMBO Mol Med. 2016 Apr 1;8(4):407-21. doi: 10.15252/emmm.201505986.

5.

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ.

Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25.

6.

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.

Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, Fernandez-Rodriguez B, Foglierini M, Agatic G, Vanzetta F, Gopal R, Langrish CJ, Barrett NA, Sallusto F, Baric RS, Varani L, Zambon M, Perlman S, Lanzavecchia A.

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8. doi: 10.1073/pnas.1510199112. Epub 2015 Jul 27.

7.

Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.

Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM.

Vaccine. 2015 Apr 21;33(17):2086-95. doi: 10.1016/j.vaccine.2015.02.020. Epub 2015 Mar 11.

8.

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies.

Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S, Preite S, Fuschillo D, Percivalle E, Sallusto F, Gerna G, Corti D, Lanzavecchia A.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17965-70. doi: 10.1073/pnas.1415310111. Epub 2014 Dec 1.

9.

Rapid development of broadly influenza neutralizing antibodies through redundant mutations.

Pappas L, Foglierini M, Piccoli L, Kallewaard NL, Turrini F, Silacci C, Fernandez-Rodriguez B, Agatic G, Giacchetto-Sasselli I, Pellicciotta G, Sallusto F, Zhu Q, Vicenzi E, Corti D, Lanzavecchia A.

Nature. 2014 Dec 18;516(7531):418-22. doi: 10.1038/nature13764. Epub 2014 Oct 5.

PMID:
25296253
10.

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, Baldanti F, Lanzavecchia A.

Nature. 2013 Sep 19;501(7467):439-43. doi: 10.1038/nature12442. Epub 2013 Aug 18.

PMID:
23955151
11.

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A.

Science. 2011 Aug 12;333(6044):850-6. doi: 10.1126/science.1205669. Epub 2011 Jul 28.

12.

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV.

Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ, Villinger F, Ibegbu C, Patel K, Corti D, Agatic G, Vanzetta F, Bianchi S, Heeney JL, Sallusto F, Lanzavecchia A, Ruprecht RM.

PLoS One. 2011 Mar 31;6(3):e18207. doi: 10.1371/journal.pone.0018207.

13.

Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Sabin C, Corti D, Buzon V, Seaman MS, Lutje Hulsik D, Hinz A, Vanzetta F, Agatic G, Silacci C, Mainetti L, Scarlatti G, Sallusto F, Weiss R, Lanzavecchia A, Weissenhorn W.

PLoS Pathog. 2010 Nov 18;6(11):e1001195. doi: 10.1371/journal.ppat.1001195.

Supplemental Content

Loading ...
Support Center